Pathogenetic aspects of responsiveness to ondansetron (5-hydroxytryptamine type 3 receptor antagonist) in patients with primary fibromyalgia syndrome - A preliminary study

Journal of Rheumatology

Volumn 23, Issue 8, 1996, Pages 1418-1423

  Hrycaj, Pawel ^a   Stratz, Thomas ^b,c   Mennet, Pierre ^b,c   Müller, Wolfgang ^b,c  

^a POZNAN UNIVERSITY OF MEDICAL SCIENCES   (Poland)

^b Hochrhein Inst fur Rehab Forsch   (Germany)

^c Hochrhein Inst Rehab Research   (Switzerland)

Author keywords

Ondansetron; Pathogenesis; Primary fibromyalgia; Therapy

Indexed keywords

ONDANSETRON; PARACETAMOL;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; FEMALE; FIBROMYALGIA; HUMAN; MALE; PATHOGENESIS; PRIORITY JOURNAL; RASH;

ACETAMINOPHEN; ADULT; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; FEMALE; FIBROMYALGIA; HUMANS; MALE; MIDDLE AGED; ONDANSETRON; PAIN MEASUREMENT; SEROTONIN;

EID: 0029762806     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (43)

1. Yunus M, Masi AT, Calabro JJ, Miller KA, Feigenbaum SL: Primary fibromyalgia (fibrositis): Clinical study of 50 patients with matched normal controls. Semin Arthritis Rheum 1981;11:151-71.
2. Boissevain MD, McCain GA: Toward an integrated understanding of fibromyalgia syndrome. I. Medical and pathophysiological aspects. Pain 1991;45:227-38.
3. Wolfe F: Fibromyalgia: The clinical syndrome. Rheum Dis Clin North Am 1989;15:1-17.
4. Carette S, McCain GA, Bell DA, Fam AG: Evaluation of amitriptyline in primary fibrositis. A double-blind, placebo-controlled study. Arthritis Rheum 1986;29:655-9.
5. Goldenberg DL, Felson DT, Dinerman H: A randomized, controlled trial of amitriptyline in the treatment of patients with fibromyalgia. Arthritis Rheum 1986;29:1371-7.
6. Goldenberg DL: Management of fibromyalgia syndrome. Rheum Dis Clin North Am 1989;15:499-512.
7. Messing RB, Lytle LD: Serotonin-containing neurons: Their possible role in pain and analgesia. Pain 1977;4;1-21.
8. Willis WD: The Pain System. The Neural Basis of Nociceptive Transmission in the Mammalian Nervous System. Basel, New York: Karger, 1985.
9. Holsboer F: Serotonin and sleep regulation. Clin Neuropharmacol 1992;(suppl 1 part A)15:349A-350A.
10. Meltzer HY, Lowy MT: The serotonin hypothesis of depression. In: Meltzer HY, ed. Psychopharmacology: The Third Generation of Progress. New York: Raven Press, 1987.
11. Russell IJ, Michalek JE, Vipraio GA, Fletcher EM, Wall K: Serum amino acids in fibrositis/fibromyalgia syndrome. J Rheumatol 1989;(suppl 19)16:158-63.
12. Yunus MB, Dailey JW, Aldag JC, Masi AT, Jobe PC: Plasma tryptophan and other amino acids in primary fibromyalgia: A controlled study. J Rheumatol 1992;19:90-4.
13. Russell IJ, Vaeroy H, Javors M, Nyberg F: Cerebrospinal fluid biogenic amine metabolites in fibromyalgia/fibrositis syndrome and rheumatoid arthritis. Arthritis Rheum 1992;35:550-6.
14. Russel IJ, Michalek JE, Vipraio GA, Fletcher EM, Javors MA, Bowden CA: Platelet 3H-imipramine uptake receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome. J Rheumatol 1992;19:104-9.
15. Hrycaj P, Stratz T, Müller W: Platelet 3H-imipramine uptake receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome (letter). J Rheumatol 1993;20:1986-7.
16. Stratz T, Samborski W, Hrycaj P, et al: Die Serotoninkonzentration im Serum bei Patienten mit generalisierter Tendomyopathie (Fibromyalgie) und chronischer Polyarthritis. Med Klin 1993;88:458-62.
17. Ballinger BR, Feely J: Antidepressants. BMJ 1983;286:1885-7.
18. Brodde O-E: 5-hydroxytryptamine-receptor subtypes. Clin Physiol Biochem 1990;(suppl 3)8:19-27.
19. Jaeschke R, Adachi J, Guyatt G, Keller J, Wong B: Clinical usefulness of amitriptyline in fibromyalgia: The results of 23 N-of-1 randomized controlled trials. J Rheumatol 1991;18:447-51.
20. Cubbedu LX, Hoffman IS, Fuenmayor NT, Finn AL: Efficacy of ondansetron (GR 38032F) and the role of serotonin in cisplatin-induced nausea and vomiting. N Engl J Med 1990;322:810-6.
21. Marty M, Pouillart P, Scholl S, et al: Comparison of the 5-hydroxytryptamine3 (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis. N Engl J Med 1990;322:816-21.
22. Broocks A: Ondansetron - der erste hochselektive 5-HT3-Antagonist in der Therapie psychiatrischer Erkrankungen. Fortschr Neurol Psychiat 1992;60:227-36.
23. Tyers MB: 5-HT3 receptors and the therapeutic potential of 5-HT3 receptor antagonists. Therapie 1991;46:431-5.
24. Costall B, Naylor RJ: Pharmacological properties and functions of central 5-HT3 receptors. Therapie 1991;46:437-44.
25. Giordano J, Rogers LV: Peripherally administered serotonin 5-HT3 receptor antagonists reduce inflammatory pain in rats. Eur J Pharmacol 1989;170:83-6.
26. Ferrari MD: 5-HT3 receptor antagonists and migraine therapy. J Neurol 1991;238:S53-S56.
27. Wolfe F, Smythe HA, Yunus MB, et al: The American College of Rheumatology 1990 criteria for the classification of fibromyalgia. Arthritis Rheum 1990;33:160-72.
28. Lautenschläger J, Brückle W, Seglias J, Müller W: Lokalisierte Druckschmerzen in der Diagnose der generalisierten Tendomyopathie (Fibromyalgie). Z Rheumatol 1989;48:132-8.
29. Huskisson EC: Measurement of pain. Lancet 1974;2:1127-31.
30. Lautenschläger J, Seglias J, Brückle W, Müller W: Comparisons of spontaneous pain and tenderness in patients with primary fibromyalgia. Clin Rheumatol 1991;10:168-74.
31. Lautenschläger J, Brückle W, Schnorrenberger CC, Müller W: Die Messung von Druckschmerzen im Bereich von Sehnen und Muskeln bei Gesunden und Patienten mit generalisierter Tendomyopathie (Fibromyalgia-Syndrom). Z Rheumatol 1988;47:397-404.
32. Glaum SR, Anderson EG: Identification of 5-HT3 binding sites in rat spinal cord synaptosomal membranes. Eur J Pharmacol 1988;156:287-90.
33. Fozard JR: Neuronal 5-HT receptors in the periphery. Neuropharmacology 1984;23:1413-6.
34. Barnes NM, Costall B, Naylor RJ: [3H]Zacopride, ligand for the identification of 5-HT3 recognition sites. J Pharm Pharmacol 1988;40:548-51.
35. Kilpatrick GJ, Jones BJ, Tyers MB: Binding of the 5-HT3 ligand, [3H]GR65630, to rat area postrema, vagus nerve and the brains of several species. Eur J Pharmacol 1989;159:157-64.
36. Sufka KJ, Giordano J: Analgesic effects of S and R isomers of the novel 5-HT3 receptor antagonists ADR-851 and ADR-852 in rats. Eur J Pharmacol 1991;204:117-9.
37. Crisp T, Stafinsky JL, Uram M, Perni VC, Weaver MF, Spanos LJ: Serotonin contributes to the spinal antinociceptive effects of morphine. Pharmacol Biochem Behav 1991;39:591-5.
38. Nakagawa I, Omote K, Kitahata LM, Collins JG, Murata K: Serotonergic mediation of spinal analgesia and its interaction with noradrenergic systems. Anesthesiology 1990;73:474-8.
39. Giordano J: Analgesic profile of centrally administered 2-methylserotonin against acute pain in rats. Eur J Pharmacol 1991;199:233-6.
40. Yunus MB: Towards a model of pathophysiology of fibromyalgia: Aberrant central pain mechanisms with peripheral modulation (editorial). J Rheumatol 1992;19:846-50.
41. Saria A, Javorsky F, Humpel C, Gamse R: 5-HT3 receptor antagonists inhibit sensory neuropeptide release from the rat spinal cord. Neuroreport 1990;1:104-6.
42. Russell IJ, Michalek JE, Vipraio GA: Serotonin (5HT) in serum and platelets from fibromyalgia patients and normal controls (abstr). J Musculoskel Pain 1995;(suppl 1)3:144.
43. Peroutka SJ: Developments in 5-hydroxytryptamine receptor pharmacology in migraine. Neurol Clin 1990;8:829-39.